Index -
P/E -
EPS (ttm) -2.21
Insider Own 1.50%
Shs Outstand 188.88M
Perf Week -5.54%
Market Cap 107.45M
Forward P/E -
EPS next Y -0.69
Insider Trans -3.04%
Shs Float 185.37M
Perf Month -22.01%
Income -414.80M
PEG -
EPS next Q -0.28
Inst Own 94.80%
Short Float / Ratio 5.45% / 2.02
Perf Quarter -50.84%
Sales 88.80M
P/S 1.21
EPS this Y 31.20%
Inst Trans -4.28%
Short Interest 10.10M
Perf Half Y -79.90%
Book/sh 1.28
P/B 0.46
EPS next Y 47.90%
ROA -56.90%
Target Price 2.38
Perf Year -84.27%
Cash/sh 2.49
P/C 0.24
EPS next 5Y -7.30%
ROE -112.20%
52W Range 0.58 - 5.18
Perf YTD -74.12%
Dividend -
P/FCF -
EPS past 5Y -32.10%
ROI -103.50%
52W High -88.71%
Beta 1.09
Dividend % -
Quick Ratio 7.90
Sales past 5Y -21.40%
Gross Margin 73.70%
52W Low 0.84%
ATR 0.05
Employees 216
Current Ratio 8.20
Sales Q/Q -12.90%
Oper. Margin -
RSI (14) 32.67
Volatility 4.11% 6.23%
Optionable Yes
Debt/Eq 0.00
EPS Q/Q -49.20%
Profit Margin -
Rel Volume 0.61
Prev Close 0.60
Shortable Yes
LT Debt/Eq 0.00
Earnings May 09 AMC
Payout -
Avg Volume 5.00M
Price 0.58
Recom 3.30
SMA20 -11.46%
SMA50 -22.23%
SMA200 -74.99%
Volume 3,025,073
Change -2.90%
Date
Action
Analyst
Rating Change
Price Target Change
May-10-23 Upgrade
Jefferies
Underperform → Hold
$1.50 → $1
Feb-24-23 Downgrade
Jefferies
Hold → Underperform
$3.20 → $1.50
Aug-08-22 Downgrade
JP Morgan
Neutral → Underweight
May-31-22 Resumed
Jefferies
Hold
$12 → $4
Apr-18-22 Downgrade
Goldman
Neutral → Sell
$3
Mar-15-22 Downgrade
Mizuho
Buy → Neutral
$35 → $8
Mar-15-22 Downgrade
Cowen
Outperform → Market Perform
Mar-14-22 Downgrade
William Blair
Outperform → Mkt Perform
Mar-14-22 Downgrade
Stifel
Buy → Hold
$24 → $5
Mar-14-22 Downgrade
BTIG Research
Buy → Neutral
Mar-14-22 Downgrade
BofA Securities
Neutral → Underperform
$18 → $6
Mar-09-22 Upgrade
Oppenheimer
Perform → Outperform
$21
Nov-08-21 Upgrade
The Benchmark Company
Hold → Buy
$20
Sep-10-21 Initiated
BofA Securities
Neutral
$18
Jun-28-21 Upgrade
Stifel
Hold → Buy
$22 → $24
May-18-21 Resumed
Goldman
Neutral
$24
Feb-22-21 Downgrade
The Benchmark Company
Buy → Hold
Jan-06-21 Initiated
Stifel
Hold
$18
Sep-14-20 Initiated
JP Morgan
Neutral
$26
Jun-10-20 Downgrade
CFRA
Hold → Sell
Show Previous Ratings
Jun-08-23 12:55PM
11:31AM
May-10-23 11:28AM
09:16AM
May-09-23 06:45PM
05:41PM
Loading…
05:41PM
04:15PM
May-08-23 09:29AM
May-04-23 10:00AM
May-02-23 10:01AM
Apr-27-23 08:30AM
Apr-19-23 08:38AM
Apr-17-23 05:00PM
Apr-16-23 06:30AM
Apr-13-23 10:59AM
08:57AM
Loading…
Apr-11-23 08:57AM
Apr-10-23 10:07AM
Apr-02-23 08:27AM
Mar-30-23 11:30AM
Mar-29-23 05:44PM
Mar-24-23 12:00PM
Mar-22-23 09:35AM
Mar-14-23 03:43AM
Feb-28-23 05:15PM
Feb-24-23 10:23AM
07:29AM
Feb-23-23 06:20PM
05:24PM
04:30PM
Jan-09-23 09:04AM
09:00AM
Loading…
Jan-04-23 09:00AM
Dec-12-22 10:05AM
Dec-05-22 08:00AM
Nov-10-22 09:05AM
07:58AM
Nov-09-22 09:00AM
Nov-04-22 12:35PM
Nov-03-22 06:35PM
Oct-28-22 10:00AM
Oct-27-22 10:02AM
Oct-25-22 06:00PM
Oct-24-22 07:55AM
Oct-11-22 05:13PM (American City Business Journals)
Oct-07-22 03:42PM (American City Business Journals)
11:21AM
Sep-07-22 01:15AM
Aug-21-22 09:57AM
Aug-16-22 08:30AM
Aug-05-22 12:11PM
Aug-04-22 06:15PM
04:15PM
Jul-26-22 06:00PM
Jul-14-22 06:01AM
Jul-01-22 06:30AM
May-27-22 08:00AM (American City Business Journals)
May-16-22 02:09PM
May-06-22 10:07AM
May-05-22 05:55PM
May-04-22 08:15AM
Apr-28-22 03:02PM
Apr-27-22 12:00PM
Apr-26-22 09:19AM
08:53AM
Apr-25-22 06:00PM (American City Business Journals)
05:57PM
04:30PM
Apr-22-22 08:30AM
Apr-20-22 12:54PM
09:17AM
Apr-18-22 05:25PM (American City Business Journals) -23.05%
11:30AM
10:39AM
09:48AM
09:32AM
Apr-14-22 04:42PM
04:30PM
Apr-05-22 05:50AM
Mar-30-22 11:30AM
Mar-16-22 12:32PM
Mar-15-22 10:38AM
Mar-14-22 05:43PM (American City Business Journals) -60.87%
04:27PM (Investor's Business Daily)
12:01PM
08:20AM
07:40AM
07:05AM
06:59AM
Mar-04-22 09:22AM
Mar-01-22 10:43AM
09:55AM
Feb-28-22 05:35PM
04:15PM
Feb-17-22 06:00PM
03:02PM
Feb-08-22 09:38AM
Feb-03-22 01:38PM
Jan-31-22 03:35PM (American City Business Journals)
Jan-21-22 01:38PM
Jan-20-22 09:38PM
Jan-19-22 01:38PM
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 1B clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1/2 clinical trial for the treatment of non-Hodgkin's lymphoma and multiple myeloma, and head and neck cancer squamous cell carcinoma and colorectal cancer. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Baxalta Incorporated; Eli Lilly and Company; Merck KGaA; and SFJ Pharmaceuticals, Inc. The company was incorporated in 1990 and is headquartered in San Francisco, California.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
ROBIN HOWARD W President & CEO May 16 Sale 0.72 20,361 14,660 939,797 May 17 08:27 PM Zalevsky Jonathan Chief R&D Officer May 16 Sale 0.72 9,791 7,050 293,388 May 17 08:29 PM Wilson Mark Andrew Chief Legal Officer May 16 Sale 0.72 7,543 5,431 257,680 May 17 08:28 PM ROBIN HOWARD W President & CEO Feb 16 Sale 3.00 19,635 58,905 960,158 Feb 17 08:57 PM Zalevsky Jonathan Chief R&D Officer Feb 16 Sale 3.00 10,484 31,452 303,179 Feb 17 09:00 PM Thomsen Jillian B. Chief Financial Officer Feb 16 Sale 3.00 10,267 30,801 313,497 Feb 17 08:58 PM Wilson Mark Andrew Chief Legal Officer Feb 16 Sale 3.00 8,275 24,825 265,223 Feb 17 08:59 PM ROBIN HOWARD W President & CEO Nov 16 Sale 3.57 38,014 135,710 979,793 Nov 18 06:02 PM Zalevsky Jonathan Chief R&D Officer Nov 16 Sale 3.57 13,460 48,052 313,663 Nov 18 06:05 PM Thomsen Jillian B. Chief Financial Officer Nov 16 Sale 3.57 11,095 39,609 323,764 Nov 18 06:03 PM Wilson Mark Andrew Chief Legal Officer Nov 16 Sale 3.57 8,690 31,023 272,498 Nov 18 06:04 PM Curet Myriam Director Sep 23 Sale 3.16 4,198 13,266 31,777 Sep 26 07:32 PM Ajer Jeffrey Robert Director Sep 23 Sale 3.16 4,198 13,266 38,512 Sep 26 07:25 PM CHESS ROBERT Director Sep 22 Sale 3.19 5,100 16,269 228,179 Sep 26 07:23 PM EASTHAM KARIN Director Sep 13 Sale 3.61 21,267 76,774 13,033 Sep 14 06:01 PM Zalevsky Jonathan Chief R&D Officer Aug 18 Sale 4.65 73,716 342,779 327,123 Aug 19 06:27 PM ROBIN HOWARD W President & CEO Aug 16 Sale 4.76 13,759 65,493 1,017,807 Aug 17 07:39 PM Zalevsky Jonathan Chief R&D Officer Aug 16 Sale 4.76 10,560 50,266 400,839 Aug 17 07:41 PM Wilson Mark Andrew SVP & General Counsel Aug 16 Sale 4.76 3,189 15,180 281,188 Aug 17 07:40 PM Thomsen Jillian B. SVP & Chief Accounting Officer Aug 16 Sale 4.76 2,006 9,549 334,859 Aug 17 07:40 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite